Clinical Trials Insight: 700025518
Phase of Trial: Phase II
Latest Information Update: 12 Oct 2007
At a glance
- Drugs CX 717 (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors RespireRx Pharmaceuticals
- 12 Oct 2007 Status changed from planning to discontinued.
- 01 Aug 2007 New trial record.